Long-Term Effects of CAR-T on Children’s Brains Remain Largely Unknown and More Research is Needed
February 26th 2024Juliane Gust, MD, PhD, an assistant professor of neurology at University of Washington, Seattle Children's, discussed a study that is currently underway via the NIH’s CARnation Consortium that will seek to address this gap in knowledge.
Zachary Crees, MD, on the Potential of Cell Therapy to Treat or Prevent Viral Infections After HSCT
February 22nd 2024The assistant clinical director of the Center for Gene and Cellular Immunotherapy at Washington University in St. Louis discussed Atara Biotherapeutics' tabelecleucel and AlloVir’s posoleucel.
Juliane Gust, MD, PhD, on Evaluating Longterm Neurological Outcomes for CAR-T in Pediatric Patients
February 21st 2024The assistant professor of neurology at University of Washington, Seattle Children's discussed efforts to address a gap in knowledge in the long-term effects of CAR-T, if any, on children’s neurological development.
Slow-and-Steady Is the Right Approach for Evaluating Cell Therapy for Autoimmune Diseases
February 18th 2024Peter A. Merkel, MD, MPH, the chief of the Division of Rheumatology and a professor of medicine and professor of epidemiology at Penn Medicine, discussed clinical trial design considerations for this emerging field.
FDA Greenlights Lifileucel for Unresectable, Metastatic Melanoma Via Accelerated Approval
February 16th 2024Iovance’s tumor infiltrating lymphocyte (TIL) therapy is the first cellular therapy to earn this indication, with the phase 3, confirmatory TILVANCE-301 trial set to verify its clinical benefit.